SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,010,983 | -10.0% | 544,468 | -1.9% | 0.95% | +0.7% |
| Q2 2023 | $16,677,081 | -16.5% | 554,793 | +0.6% | 0.95% | -16.7% |
| Q1 2023 | $19,973,056 | -9.6% | 551,285 | -11.0% | 1.14% | -10.4% |
| Q4 2022 | $22,091,394 | -3.9% | 619,327 | -8.8% | 1.27% | -5.0% |
| Q3 2022 | $22,995,000 | -4.7% | 679,311 | -18.5% | 1.33% | +14.3% |
| Q2 2022 | $24,118,000 | -12.7% | 833,952 | -2.5% | 1.17% | +5.9% |
| Q1 2022 | $27,632,000 | +10.6% | 854,949 | -0.2% | 1.10% | +24.1% |
| Q4 2021 | $24,986,000 | +2.4% | 856,855 | -6.3% | 0.89% | -1.7% |
| Q3 2021 | $24,400,000 | -14.1% | 914,881 | -0.9% | 0.90% | -10.8% |
| Q2 2021 | $28,415,000 | +4.9% | 922,859 | -10.8% | 1.01% | +14.5% |
| Q1 2021 | $27,099,000 | +3.8% | 1,035,089 | -0.2% | 0.88% | -3.8% |
| Q4 2020 | $26,100,000 | +24.0% | 1,037,378 | +2.7% | 0.92% | +8.3% |
| Q3 2020 | $21,040,000 | -4.3% | 1,009,614 | +9.1% | 0.85% | -10.1% |
| Q2 2020 | $21,980,000 | +28.9% | 925,486 | -2.3% | 0.94% | -1.0% |
| Q1 2020 | $17,047,000 | -25.3% | 947,555 | -1.5% | 0.95% | +23.4% |
| Q4 2019 | $22,818,000 | -11.4% | 961,973 | +2.7% | 0.77% | -16.2% |
| Q3 2019 | $25,751,000 | -42.4% | 937,073 | -30.7% | 0.92% | -38.0% |
| Q2 2019 | $44,714,000 | +27.6% | 1,351,286 | +35.1% | 1.48% | +31.5% |
| Q1 2019 | $35,053,000 | +15.5% | 1,000,381 | +9.5% | 1.13% | +2.0% |
| Q4 2018 | $30,354,000 | -5.6% | 913,736 | +43.0% | 1.11% | -3.8% |
| Q3 2018 | $32,168,000 | -33.0% | 638,892 | -20.4% | 1.15% | -34.1% |
| Q2 2018 | $48,039,000 | -19.4% | 802,661 | -38.3% | 1.75% | -24.9% |
| Q1 2018 | $59,619,000 | +13.1% | 1,301,728 | -1.6% | 2.33% | +12.3% |
| Q4 2017 | $52,706,000 | +7.6% | 1,322,614 | +8.0% | 2.07% | -4.4% |
| Q3 2017 | $48,973,000 | -16.5% | 1,224,317 | -10.1% | 2.17% | -15.1% |
| Q2 2017 | $58,675,000 | +71.4% | 1,361,373 | +24.5% | 2.55% | +53.1% |
| Q1 2017 | $34,223,000 | +25.3% | 1,093,402 | +1.1% | 1.67% | +21.1% |
| Q4 2016 | $27,314,000 | +82.8% | 1,081,740 | +79.0% | 1.38% | +76.3% |
| Q3 2016 | $14,943,000 | +34.9% | 604,242 | +11.2% | 0.78% | +22.4% |
| Q2 2016 | $11,073,000 | +35.4% | 543,606 | +1.3% | 0.64% | +35.2% |
| Q1 2016 | $8,181,000 | +27.6% | 536,445 | +12.4% | 0.47% | +29.0% |
| Q4 2015 | $6,412,000 | +123.0% | 477,068 | +132.8% | 0.37% | +96.8% |
| Q3 2015 | $2,875,000 | +50.9% | 204,887 | +82.6% | 0.19% | +69.1% |
| Q2 2015 | $1,905,000 | – | 112,189 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |